These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21986283)

  • 1. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Plouin PF
    J Hypertens; 2013 Mar; 31(3):624-9; discussion 629. PubMed ID: 23314743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
    Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
    J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
    Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
    Andersen K; Hartman D; Peppard T; Hermann D; Van Ess P; Lefkowitz M; Trapani A
    J Clin Hypertens (Greenwich); 2012 Sep; 14(9):580-7. PubMed ID: 22947355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
    Johnson AG; Pearce GL; Danoff TM
    J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
    Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
    J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review.
    Wang HZ; Tian JB; Yang KH
    Eur Rev Med Pharmacol Sci; 2015; 19(2):296-304. PubMed ID: 25683946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
    Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
    JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension.
    Whelton A; Dunne B; Glazer N; Kostis JB; Miller WE; Rector DJ; Tresznewsky ON
    J Hum Hypertens; 1992 Aug; 6(4):325-31. PubMed ID: 1331444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.